阿加曲班治疗进展性脑梗死的临床观察

Clinical Research of Argatroban in the Treatment of Progressive Cerebral Infarction

目的:评价阿加曲班治疗急性进展性脑梗死的临床疗效,探讨进展性脑梗死的有效治疗方法。方法:将60例急性进展性脑梗死患者随机分为两组,各30例。治疗组给予阿加曲班加红花注射液,对照组给予红花注射液加奥扎格雷。治疗期间两组根据基础疾病,酌情给予降压、调控血糖、脱水、脑保护等治疗。两组治疗前及14d后进行NIHSS评分(主要指标)及改良RANKIN评分。记录治疗过程中出现的不良事件。结果:(1)治疗组14d后NIHSS评分及改良RANKIN评分均低于治疗前差异有统计学意义(P<0.01),14d后两组比较差异也有统计学意义(P<0.05);(2)治疗组总有效率为93.3%,对照组总有效率为76.7%,两组间比较差异无统计学意义(P>0.05)。结果显示两种药物治疗急性进展性脑梗死患者均有较好疗效;阿加曲班组疗效优于对照组。结论:进展性脑梗死应用阿加曲班治疗安全有效,值得临床推广。

Objective：To evaluate the efficacy and safety of argatroban in the treatment of progressive cerebral infarc- tion, and to investigate the effective treatment on progressive cerebral infarction. Methods： 60 cases of progressive cere- bral infraction were randomly divided into two groups.argatroban treatment group （n=30） and conventional treatment group （n= 30）. Treatment group was treated with venous argatroban and Safflower injection. Conventional treatment group was given venous Safflower injection and Sodium Ozagrel. During treatment, two groups were regulated blood sugar and blood pressure, and other neurotroptfic drugs treatment according to the basical diseases. NIHSS scores （main index） and improved RANKIN scores were given after treatment of 14d. Adverse events were recorded in the process of treatment. Results： The scores of NIHSS and improved RANKIN with argatroban had statistically greatly improved than the scores before curing （P〈0. 01）. The results of ozagrel also showed a remarkable improvement in NIHSS and improved RANKIN （P〈0. 05）. The effective rate of the two groups： the argatroban group is 93.3% and the ozagrel group is 76. 7%. The rate of the two groups had no significant difference （P〉0.05）. The two durgs are both effective to the treatment of PCI. Therapeutic evaluation of argatroban group is better than that of ozagrel group. Conclusion： Argatroban could greatly improve patients＇ neurological symptoms. In a word, argatroban is a safe and ef- fective drug for patients with progressive cerebral infarction.